Clinical Trial Update: Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the immunogenicity of a synthetic melanoma peptide vaccine administered with GM-CSF in combination with systemic low-dose interleukin-2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Leukine (sargramostim)
• Proleukin (aldesleukin)
• Synthetic Melanoma Peptides Vaccine

Snippet

Sponsor: University of Virginia | Conditions: Melanoma | Phase 2 | Status: COMPLETED